Abstract
Despite favourable mortality rates, up to 30% of PTC patients suffer recurrence. The current widely used circulating biomarker, thyroglobulin (Tg), is unreliable in up to 25% of these patients. Therefore, a systemic biomarker of PTC may circumvent some of the issues associated with Tg, and may also be an adjunct to FNA in the diagnosis of PTC. We aimed to measure the levels of plasma miRNAs which are over-expressed in PTC tissue, and to demonstrate a reduction in their levels after removal of macroscopic malignant tissue.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
